Aurolife Pharma Recalls Fexofenadine Hydrochloride Tablets Due to Impurity Failures
Aurolife Pharma is recalling 8,240 bottles of Fexofenadine Hydrochloride 180 mg tablets nationwide because they failed impurity and degradation specifications.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text identifies this as an FDA Class II recall. Per the rubric, FDA Class II recalls are classified as Severe (Score 4), particularly when involving structural or chemical specification failures like impurities.
Plain-English summary
Aurolife Pharma, LLC is recalling 8,240 bottles of Fexofenadine Hydrochloride Tablets USP, 180 mg, 100-count bottles. The product is distributed by Aurohealth LLC and carries the NDC 58602-711-21. The specific lot number is 067180008A with an expiration date of 03/21.
The recall was initiated because the product failed impurities and degradation specifications. This is an FDA Class II recall, indicating a situation where use of, or exposure to, the violation may cause temporary or medically reversible adverse health consequences.
The affected product was distributed nationwide in the USA. Consumers who have this specific lot of medication should stop using it and contact their healthcare provider or pharmacist for guidance on disposal or replacement.
The recalled product
- Product
- Fexofenadine Hydrochrloride Tablets USP, 180 mg, 100-count bottle, Distributed by: Aurohealth LLC., 2572 Brunswick Pike, Lawrenceville, NJ 08648, NDC 58602-711-21
- Manufacturer
- Aurolife Pharma, LLC
- Category
- Drug — Antihistamine
- Hazard
- Affected units
- 8,240
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 067180008A
- Exp 03/21
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 11 recalled by Aurolife Pharma, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Aurolife Pharma, LLC
See all →- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- HighGlycopyrrolate Tablets Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2022-12-28
- HighGlycopyrrolate Tablets Recalled Due to Glass Pieces in Sealed Bottles
FDA (Drugs) · 2022-04-06
- SevereAurolife Recalls Fexofenadine Hydrochloride Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
- SevereAurolife Pharma Recalls Fexofenadine HCL Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08